159 related articles for article (PubMed ID: 38201278)
1. Sox10-Deficient Drug-Resistant Melanoma Cells Are Refractory to Oncolytic RNA Viruses.
Abou-Hamad J; Hodgins JJ; Yakubovich E; Vanderhyden BC; Ardolino M; Sabourin LA
Cells; 2023 Dec; 13(1):. PubMed ID: 38201278
[TBL] [Abstract][Full Text] [Related]
2. Cooperative induction of receptor tyrosine kinases contributes to adaptive MAPK drug resistance in melanoma through the PI3K pathway.
Alver TN; Heintz KM; Hovig E; Bøe SL
Cancer Rep (Hoboken); 2023 Feb; 6(2):e1736. PubMed ID: 36251678
[TBL] [Abstract][Full Text] [Related]
3. Cell Cycle Arrest in G
Bressy C; Droby GN; Maldonado BD; Steuerwald N; Grdzelishvili VZ
J Virol; 2019 Feb; 93(4):. PubMed ID: 30487274
[TBL] [Abstract][Full Text] [Related]
4. Modulation of the Type I Interferon Response Defines the Sensitivity of Human Melanoma Cells to Oncolytic Measles Virus.
Allagui F; Achard C; Panterne C; Combredet C; Labarrière N; Dréno B; Elgaaied AB; Pouliquen D; Tangy F; Fonteneau JF; Grégoire M; Boisgerault N
Curr Gene Ther; 2017; 16(6):419-428. PubMed ID: 28042780
[TBL] [Abstract][Full Text] [Related]
5. Interferon Beta and Interferon Alpha 2a Differentially Protect Head and Neck Cancer Cells from Vesicular Stomatitis Virus-Induced Oncolysis.
Westcott MM; Liu J; Rajani K; D'Agostino R; Lyles DS; Porosnicu M
J Virol; 2015 Aug; 89(15):7944-54. PubMed ID: 25995245
[TBL] [Abstract][Full Text] [Related]
6. Ezrin Inhibition Overcomes Acquired Resistance to Vemurafenib in BRAFV600E-Mutated Colon Cancer and Melanoma Cells In Vitro.
Car I; Dittmann A; Vasieva O; Bočkor L; Grbčić P; Piteša N; Klobučar M; Kraljević Pavelić S; Sedić M
Int J Mol Sci; 2023 Aug; 24(16):. PubMed ID: 37629086
[TBL] [Abstract][Full Text] [Related]
7. Gene signature reveals decreased SOX10-dependent transcripts in malignant cells from immune checkpoint inhibitor-resistant cutaneous melanomas.
Purwin TJ; Caksa S; Sacan A; Capparelli C; Aplin AE
iScience; 2023 Sep; 26(9):107472. PubMed ID: 37636077
[TBL] [Abstract][Full Text] [Related]
8. Resistance of pancreatic cancer cells to oncolytic vesicular stomatitis virus: role of type I interferon signaling.
Moerdyk-Schauwecker M; Shah NR; Murphy AM; Hastie E; Mukherjee P; Grdzelishvili VZ
Virology; 2013 Feb; 436(1):221-34. PubMed ID: 23246628
[TBL] [Abstract][Full Text] [Related]
9. Novel biomarkers of resistance of pancreatic cancer cells to oncolytic vesicular stomatitis virus.
Hastie E; Cataldi M; Moerdyk-Schauwecker MJ; Felt SA; Steuerwald N; Grdzelishvili VZ
Oncotarget; 2016 Sep; 7(38):61601-61618. PubMed ID: 27533247
[TBL] [Abstract][Full Text] [Related]
10. SOX10 deficiency-mediated LAMB3 upregulation determines the invasiveness of MAPKi-resistant melanoma.
Han S; Zhang M; Qu X; Wu Z; Huang Z; Hu Y; Li Y; Cui L; Si L; Liu J; Shao Y
Oncogene; 2024 Feb; 43(6):434-446. PubMed ID: 38102338
[TBL] [Abstract][Full Text] [Related]
11. Vesicular stomatitis virus has extensive oncolytic activity against human sarcomas: rare resistance is overcome by blocking interferon pathways.
Paglino JC; van den Pol AN
J Virol; 2011 Sep; 85(18):9346-58. PubMed ID: 21734048
[TBL] [Abstract][Full Text] [Related]
12. Combination of oncolytic adenovirus and dacarbazine attenuates antitumor ability against uveal melanoma cells via cell cycle block.
Cun B; Song X; Jia R; Zhao X; Wang H; Ge S; Fan X
Cancer Biol Ther; 2012 Jan; 13(2):77-84. PubMed ID: 22336909
[TBL] [Abstract][Full Text] [Related]
13. [Oncolytic Properties of a Mumps Virus Vaccine Strain in Human Melanoma Cell Lines].
Ammour YI; Ryabaya OO; Milovanova AV; Sidorov AV; Shohin IE; Zverev VV; Nasedkina TV
Mol Biol (Mosk); 2018; 52(4):659-666. PubMed ID: 30113031
[TBL] [Abstract][Full Text] [Related]
14. Silencing of Mcl-1 overcomes resistance of melanoma cells against TRAIL-armed oncolytic adenovirus by enhancement of apoptosis.
Tolksdorf B; Zarif S; Eberle J; Hazini A; Dieringer B; Jönsson F; Kreppel F; Kurreck J; Fechner H
J Mol Med (Berl); 2021 Sep; 99(9):1279-1291. PubMed ID: 34028599
[TBL] [Abstract][Full Text] [Related]
15. Constitutive low expression of antiviral effectors sensitizes melanoma cells to a novel oncolytic virus.
Dellac S; Ben-Dov H; Raanan A; Saleem H; Zamostiano R; Semyatich R; Lavi S; Witz IP; Bacharach E; Ehrlich M
Int J Cancer; 2021 May; 148(9):2321-2334. PubMed ID: 33197301
[TBL] [Abstract][Full Text] [Related]
16. Single-cycle viral gene expression, rather than progressive replication and oncolysis, is required for VSV therapy of B16 melanoma.
Galivo F; Diaz RM; Wongthida P; Thompson J; Kottke T; Barber G; Melcher A; Vile R
Gene Ther; 2010 Feb; 17(2):158-70. PubMed ID: 20016540
[TBL] [Abstract][Full Text] [Related]
17. A monocentric phase I study of vemurafenib plus cobimetinib plus PEG-interferon (VEMUPLINT) in advanced melanoma patients harboring the V600BRAF mutation.
Simeone E; Scognamiglio G; Capone M; Giannarelli D; Grimaldi AM; Mallardo D; Madonna G; Curvietto M; Esposito A; Sandomenico F; Sabbatino F; Bayless NL; Warren S; Ong S; Botti G; Flaherty KT; Ferrone S; Ascierto PA
J Transl Med; 2021 Jan; 19(1):17. PubMed ID: 33407577
[TBL] [Abstract][Full Text] [Related]
18. Reversible and adaptive resistance to BRAF(V600E) inhibition in melanoma.
Sun C; Wang L; Huang S; Heynen GJ; Prahallad A; Robert C; Haanen J; Blank C; Wesseling J; Willems SM; Zecchin D; Hobor S; Bajpe PK; Lieftink C; Mateus C; Vagner S; Grernrum W; Hofland I; Schlicker A; Wessels LF; Beijersbergen RL; Bardelli A; Di Nicolantonio F; Eggermont AM; Bernards R
Nature; 2014 Apr; 508(7494):118-22. PubMed ID: 24670642
[TBL] [Abstract][Full Text] [Related]
19. Engineered oncolytic viruses to treat melanoma: where are we now and what comes next?
Rothermel LD; Zager JS
Expert Opin Biol Ther; 2018 Dec; 18(12):1199-1207. PubMed ID: 30392405
[TBL] [Abstract][Full Text] [Related]
20. Vesicular stomatitis virus variants selectively infect and kill human melanomas but not normal melanocytes.
Wollmann G; Davis JN; Bosenberg MW; van den Pol AN
J Virol; 2013 Jun; 87(12):6644-59. PubMed ID: 23552414
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
